Cardiovascular Prevention
12
4
4
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP)
A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet Therapy
The YOU-Fish Study: Fish and Omega 3 Supplementation in Young Adults
Randomized, Double-blind Crossover Trial Comparing Low-GI Functional vs. Standard Wholegrain Carbohydrates on Glycolipid Metabolism and Vascular Stress Markers in Adults With Suboptimal Triglyceridemia
Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention
Connect2Move: Valorization of Natural Cardio Trekking Hiking Trails
The Cardiovascular Prevention Program
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
New Cardiovascular Risk Screening Strategy.
Cardiac Rehabilitation for Cardiovascular Risk Reduction in People With Severe and Persistent Mental Illness
Web-based Motor Intervention to Increase Health Related Physical Fitness in Children With Congenital Heart Disease
Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy